12:16 PM EDT, 04/21/2026 (MT Newswires) -- Smith &Nephew (SNN) said Tuesday that new data from a clinical trial show "compelling"long-term results for its CARTIHEAL AGILI-C cartilage repair implant.

The company said the study found the implant outperformed standard surgical care across all measured time points up to five years, adding that the patients treated with the implant reported better pain relief and improved quality of life over the five-year period. They also showed greater improvements in daily activities, sports, and recreation at two, four, and five years after treatment, according to a statement.

The study also found similar outcomes in patients with and without osteoarthritis, the company added.

The implant recently received a category one current procedural terminology code for procedures that will take effect on Jan. 1, 2027, the company said.

Shares of Smith &Nephew were down nearly 3.4% in the session.

Price: 33.04, Change: -1.17, Percent Change: -3.42